免疫干扰再探讨:黄热病疫苗接种前接种减毒活流感疫苗的影响
研究纳入660名接种减毒活流感疫苗(LAIV)后接种黄热病疫苗(YF17D)的军人,比较按指南接种组(507人)与不按指南接种组(153人)的YF17D血清转化率。结果显示两组血清转化率分别为97.8%和95.4%(p=0.15),无显著差异;多因素分析显示LAIV后7-21天接种YF17D及女性与血清应答降低相关。
要点
- 按指南接种组与不按指南接种组的YF17D血清转化率分别为97.8%和95.4%,无显著差异(p=0.15)。
- LAIV后7-21天接种YF17D与血清应答降低相关(aOR 0.304,p=0.017,95%CI 0.114-0.810)。
- 女性与血清应答降低相关(aOR 0.330,p=0.026,95%CI 0.124-0.879)。
核心结论
- 在健康年轻成人军人中,同时或于LAIV后不同时间点接种YF17D均可见高血清转化率,女性及LAIV后7-21天接种者血清应答略有降低。
研究设计与样本
- 研究纳入接种LAIV同时或之前、并接种YF17D且有疫苗接种前后存档血清的部署人员,共660人,其中按指南接种组507人、不按指南接种组153人。
- 按指南接种定义为YF17D与LAIV同时接种或LAIV后≥30天接种,不按指南接种定义为LAIV后1-29天接种YF17D。
- YF17D血清应答通过筛查ELISA确定,阳性ELISA样本经蚀斑减少中和试验(PRNT)确认。
- 排除标准为既往接种YF17D及接种前YF17D PRNT阳性。
主要发现
- 按指南接种组与不按指南接种组的中位年龄均为25岁。
- 按指南接种组男性占84%,不按指南接种组男性占79%(p=0.194)。
- 按指南接种组血清转化率为97.8%,不按指南接种组为95.4%(p=0.15)。
- 多因素logistic回归显示,LAIV后7-21天接种YF17D与血清应答降低相关(aOR 0.304,p=0.017,95%CI 0.114-0.810)。
- 女性与血清应答降低相关(aOR 0.330,p=0.026,95%CI 0.124-0.879)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During routine mass live-attenuated influenza vaccination (LAIV) for military personnel, emergent deployment for Ebola humanitarian assistance (OUA) required mass yellow fever vaccination (YF17D), often < 4-weeks recommended timing post-LAIV-triggering concerns for immune interference. We compared YF17D seroconversion rates in personnel who received YF17D as recommended (vaccinated by guidelines [VBG]) to those who received the vaccine outside the recommended timing following LAIV (not vaccinated by guidelines [NVBG]). METHODS: OUA deploying personnel who received LAIV simultaneously or before YF17D and had pre- and post-vaccination archived serum were included. VBG was defined as YF17D given concurrently or ≥ 30 days post-LAIV and NVBG as YF17D given 1-29 days post-LAIV. YF17D seroresponse was determined by screening ELISA confirmed with plaque reduction neutralization testing (PRNT) on positive ELISA samples. Exclusion criteria were prior YF17D and pre-vaccination YF17D positive PRNT. RESULTS: Of the 660 personnel included, 507 were VBG and 153 were NVBG. Median age was 25 years for both groups. Men accounted for 84% of those VBG and 79% NVBG (p = 0.194). Seroconversion rates were 97.8% for VBG and 95.4% for NVBG (p = 0.15). Multivariate logistic regression revealed that YF17D on days 7-21 post-LAIV (adjusted odds ratio [aOR] 0.304, p = 0.017; confidence interval [CI] 0.114-0.810) and female sex (aOR 0.330, p = 0.026; CI 0.124-0.879) were associated with decreased seroresponse. CONCLUSIONS: In this healthy, young adult military population, there was high seroconversion following YF17D when administered simultaneously and at various time points after LAIV. Slight decreases in seroresponse were seen in women and those receiving YF17D 7-21 days following LAIV.
引用
- Blyth DM, Liang Z, Williams M, et al. Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination. Vaccine. 2022. PMID: 35031146. doi:10.1016/j.vaccine.2021.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。